疏肝解郁胶囊联合艾司西酞普兰改善老年躯体疾病焦虑抑郁状态及治疗依从性研究  

Study on Effect of Shugan Jieyu Capsule Combined with Escitalopram in Treatment of Anxiety and Depression in Elderly Patients with Somatic Diseases

作　　者：李倩[1] 张玉娟[1] 王丽娜[1] 高志涛[1] 潘伟盟[1] 王秀娟[1] LI Qian;ZHANG Yujuan;WANG Lina;GAO Zhitao;PAN Weimeng;WANG Xiujuan(Department of Psychiatry, The Second Affiliated Hospital of Medical University, Xinxiang 453002, Henan, Chin)

机构地区：[1]新乡医学院第二附属医院精神科

出　　处：《中华中医药学刊》2018年第4期970-973,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：河南省科技厅项目(152400410348)

摘　　要：目的：观察疏肝解郁胶囊联合艾司西酞普兰对老年躯体疾病患者焦虑抑郁状态的改善效果,及对患者治疗依从性的影响,为改善老年躯体疾病患者焦虑抑郁状态,提高生活质量及治疗依从性的方案选择提供参考。方法：选择2015年1月—2016年1月医院收治的老年躯体疾病患者120例作为研究对象,所有患者焦虑自评量表（SAS）、抑郁自评量表评分（SDS）均〉50分,根据就诊顺序编号,采用数字随机表法将其随机分为对照组和观察组,每组60例。两组患者均根据患者的躯体疾病,采取对症治疗,对照组患者采用艾司西酞普兰治疗焦虑抑郁,观察组采用疏肝解郁胶囊联合艾司西酞普兰治疗焦虑抑郁。两组患者均连续治疗3个月,比较两组患者治疗前、后SDS评分、SAS评分、90项症状自评量表（SCL-90）的变化,比较两组患者治疗期间的服药依从性、康复锻炼依从性、治疗措施依从性、检查依从性、回院随访依从性。两组患者治疗期间药物不良反应发生率。结果：两组患者性别、年龄、文化程度、居住地、躯体疾病类型及严重程度、入组前SDS、SAS、SCL-90评分比较差异均无统计学意义（P〉0.05）。两组患者完成3个月治疗疗程后,SDS、SAS、SCL-90评分均较入组前明显降低（P〈0.05）。结论：疏肝解郁胶囊联合艾司西酞普兰可有效改善老年躯体疾病患者的焦虑抑郁状态,提升患者的治疗依从性,提高患者的生活质量,为老年躯体疾病患者获得良好预后的有效保障,具有较高的临床价值。Objective： To observe the effect of Shugan Jieyu Capsule combined with Escitalopram on the anxiety and depression of elderly patients with physical disease and effect on the compliance of patient to improve the anxiety and depression of elderly patients and the quality of life and treatment according to the selection of references. Methods： From January 2015-January 2016 in our hospital,120 cases of elderly patients with physical disease were as the research object and all patients＇ self rating Anxiety Scale（ SAS） and self rating Depression Scale（ SDS） were more than 50 points.According to the treatment sequence number,the patients were randomly divided into the control group and the observation group and 60 cases in each group. Two groups according to the patient＇s somatic disease were given the symptomatic treatment. The control group was treated with Escitalopram and the observation group added Shugan Jieyu Capsule. Two groups were continuously treated for 2 months. We compared SDS score,SAS score,symptom checklist 90（ SCL-90）changes during the treatment of the two groups and administration complicance,rehabilitation exercise compliance,treatment compliance,compliance check and back to the hospital follow-up compliance were also compared. The incidence of adverse drug reactions during the treatment of the two groups was recorded. Results： There was no significant difference in gender,age,education level,occupation,type and severity of somatic diseases,SDS,SAS,SCL-90 score before entering into the two groups（ P 〈 0. 05）. Two groups completed the treatment for 2 months. After treatment,SDS,SAS and SCL-90 scores were significantly lower than those before treatment（ P 〈 0. 05）. The observation group＇s medication compliance and rehabilitation exercise compliance rate,treatment compliance rate and check compliance rate during3 months observation period were significantly higher than those of the control group（ P 〈 0. 05）. There was no significant difference in adverse drug r

关 键 词：老年躯体疾病 焦虑 抑郁 疏肝解郁胶囊 艾司西酞普兰 治疗依从性 影响研究 

分 类 号：R749.72[医药卫生—神经病学与精神病学]